Striae Alba
Conditions
Keywords
striae alba, fractional picosecond laser, stretch marks
Brief summary
The objective of this study is to evaluate the efficacy and safety of a fractional 1,064 nm picosecond laser for the treatment of striae alba.
Detailed description
Striae distensae are atrophic dermal scars that can cause psychosocial distress on affected patients. Despite numerous available therapeutic modalities, no gold standard therapy has been established. Picosecond lasers are a newer advancement in lasers that have primarily used in the treatment of tattoos. A fractional 1064-nm picosecond laser has recently become available for the treatment of pigmentation and skin rejuvenation. The main mechanism of action is tissue ablation via laser induced optical breakdown (LIOB) which occur when pulse intensity is high enough to strip electrons and generating plasma, the plasma absorbs the remaining laser energy forming a cavitation bubble within the dermis which has been demonstrated to improve fine wrinkles and acne scar through the stimulation of collagen formation.
Interventions
The parameter of laser was 8-mm spot size, 0.6 mJ/cm2, 750 ps, 10 Hz, 2 passes. The treatment was done in every 4 weeks for 4 sessions.
Sponsors
Mahidol University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Striae alba on abdomen for more than 3 months * Fitzpatrick skin type III-V
Exclusion criteria
* Pregnancy and breastfeeding * Previous topical treatment, filler injection, chemical peel or laser treatment within 6 months before starting the study * History of using Isotretinoin * Photosensitive dermatoses, Infection, eczema * Past history or family history of malignancy * History of herpes infection * History of hypertrophic scar or keloid, connective tissue disease * History of collagen or elastin disease * History of smoking * Significant fluctuations in weight in the past 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in striae roughness by Antera 3D image | change from baseline in striae roughness score at 6 months |
| Change in average Melanin index by Antera 3D image | change from baseline in average melanin index at 6 months |
| Change in melanin variation index by Antera 3D image | change from baseline in melanin variation index at 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Investigator assessment scores | Baseline, 1, 3 and 6 months after final treatment | Clinical improvement was evaluated by comparing pre and post photographs by 2 independent investigators. |
| Patient satisfaction scores | Baseline, 1, 3, and 6 months after final treatment | patient satisfaction questionnaire was done by grading on a scale of 0 to 4; 0: no improvement, 1: \<25% improvement, 2: 25-50% improvement, 3: 51-75% improvement, 4: \> 75% improvement |
Countries
Thailand
Contacts
Primary ContactWoraphong Manuskiatti, M.D.
Backup ContactArisa Kaewkes, M.D.
Outcome results
None listed